REGENERON

REGENERON

approved_indications FDA Approved Biologics and Pending Applications

Arcalyst®

rilonacept
BL 125249

Dupixent®

dupilumab
BL 761055

Eylea®

aflibercept
BL 125387

Libtayo®

cemiplimab-rwlc
BL 761097

approved_indications Inter Partes Review Proceedings

DUPIXENTIPR2017-01129
IPR2017-01879
IPR2017-01884
EYLEAIPR2020-01317
IPR2020-01318
IPR2020-01320
GENENTECH CABILLYIPR2015-01624

approved_indications U.S. Patent Litigations

DUPIXENT1:17-cv-10465 (D. Mass.)
2:17-cv-02613 (C.D. Cal.)
EYLEA1:18-cv-02434 (S.D.N.Y.)
1:20-cv-00690 (N.D.N.Y.)
ZALTRAP1:18-cv-02434 (S.D.N.Y.)
7:11-cv-09463 (S.D.N.Y.)
EYLEA / LUCENTIS / ZALTRAP1:18-cv-02434 (S.D.N.Y.)
PRALUENT / GENENTECH CABILLY2:15-cv-05685 (C.D. Cal.)
PRALUENT / REPATHA1:14-cv-01317 (D. Del.)
1:14-cv-01349 (D. Del.)
1:14-cv-01393 (D. Del.)
1:14-cv-01414 (D. Del.)

related articles Related News Articles

Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong August 10, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong July 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. October 8, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. May 7, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. October 6, 2018

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha